Mercy BioAnalytics Valuation, Funding & Investors

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Osler Diagnostics is an Oxford-headquartered medtech company spun out from the University of Oxford in 2017. It develops the Origin device, a portable analyzer for 25 blood biomarkers including cholesterol and HbA1c, targeting point-of-care testing in clinics and homes across Europe and Africa. Osler raised GBP 12 million in Series A funding in 2022.

Osang Healthcare Co Ltd is engaged in medical device development. It develops diagnostic biosensors for blood glucose measurement, HbA1c and cholesterol , Immuno Diagnosis, Molecular Diagnosis, etc.

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases. The firm advances AAV-based therapies for X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis using its spreading capsid AAV.SPR platform. Headquartered in Raleigh, North Carolina, Atsena Therapeutics conducts trials targeting genetic mutations causing blindness.